Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Trial Profile

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Letrozole; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PHERGain
  • Sponsors Medica Scientia Innovation Research
  • Most Recent Events

    • 18 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top